Ishigooka M, Hashimoto T, Hayami S, Tomaru M, Nakada T, Mitobe K
Department of Urology, Yamagata University, School of Medicine, Japan.
Int Urol Nephrol. 1995;27(1):61-6. doi: 10.1007/BF02575222.
Eviprostat has been used as a non-hormonal and non-neuropharmacological treatment for benign prostatic hyperplasia (BPH) in Japan. We evaluated the clinical efficacy of Eviprostat in patients with symptomatic BPH and the anti-inflammatory effect of this drug was investigated by retrospective evaluation of TUR specimens. Clinically, Eviprostat subjectively relieved obstructive symptoms of BPH. Objective improvements were also demonstrated by ultrasonographic evaluation of prostatic volume and urinary flow rates. Histologically, preoperative administration of Eviprostat improved the degree of prostatic inflammation. This drug probably can have a place in the treatment of patients with mild or moderate symptoms of outflow obstruction.
爱普列特在日本已被用作治疗良性前列腺增生（BPH）的非激素和非神经药理学药物。我们评估了爱普列特对有症状BPH患者的临床疗效，并通过对经尿道前列腺切除术（TUR）标本的回顾性评估来研究该药的抗炎作用。临床上，爱普列特可主观缓解BPH的梗阻症状。通过超声评估前列腺体积和尿流率也证实了客观改善。组织学上，术前给予爱普列特可改善前列腺炎症程度。该药可能在治疗轻度或中度流出道梗阻症状的患者中占有一席之地。
